智翔金泰(688443) - 2025 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2025 reached RMB 230.72 million, a significant increase of 666.65% compared to RMB 30.09 million in the same period last year[3] - The net profit attributable to the parent company was a loss of RMB 536.22 million, which is a 32.74% reduction in losses compared to RMB 797.27 million in the previous year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of RMB 579.22 million, narrowing losses by 27.99% from RMB 804.33 million year-on-year[3] - The basic earnings per share decreased by 32.26% to RMB -1.47 from RMB -2.17 in the previous year[3] - The company reported a weighted average return on net assets of -28.93%, an improvement of 3.72 percentage points from -32.65% in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 2,992.66 million, down 4.87% from RMB 3,145.72 million at the beginning of the period[3] - Equity attributable to the parent company decreased by 25.49% to RMB 1,584.20 million from RMB 2,126.04 million year-on-year[3] Revenue Growth Drivers - The company attributed the revenue growth to the market expansion of its first commercialized product, the Saliqi monoclonal antibody injection (Jinlixi®), which saw steady sales growth[6] - The significant increase in revenue was also supported by substantial licensing income from the GR1803 injection commercialization agreement[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final results to be disclosed in the 2025 annual report[4]